<?xml version="1.0" encoding="UTF-8"?>
<p id="p0210">The air-liquid interface of human nasal epithelial cells cultures collected from patients affected by chronic rhinosinusitis were recently exposed in vitro to a 0.5% solution of PVP-I (Nasodine® licensed by Firebrick Pharma) (
 <xref rid="bib58" ref-type="bibr">Ramezanpour et al., 2020</xref>). No cell toxicity was observed on paracellular permeability or cilia beat frequency. The trans epithelial electrical resistance of cultured cells was significantly reduced only after 30 minutes exposure to Nasodine® (
 <xref rid="bib50" ref-type="bibr">Meng et al., 2020</xref>). Consequently, PVP-I could be considered as a safe therapy when used as a mouthwash or taken nasally or used during ophthalmic surgeries.
</p>
